Lauren A. Crowder

Lauren A. Crowder

Auto-generated profile, based on publicly available information

Lauren A. Crowder

Scientific Affairs American Red Cross Rockville Maryland USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Quality of Life Research
Verified
Journal Article
Open access
PDF file
JAJohn N. Aucott
John N. Aucott
ARAlison W. Rebman
Alison W. Rebman
LCLauren A. Crowder
Lauren A. Crowder
KKKathleen B. Kortte
Kathleen B. Kortte
Purpose A subset of patients treated for Lyme disease report persistent or recurrent symptoms of unknown etiology named post-treatment Lyme disease syndrome (PTLDS). This study aims to describe a cohort of participants with early, untreated Lyme disease, and characterize post-treatment symptomatology and functional impact of PTLDS over time. Methods Sixty-three participants with erythema migrans and systemic symptoms were enrolled in a prospective cohort study. Participants underwent physical exams and clinical assessments, and completed the SF-36 (daily life functioning) and the Beck Depression Inventory, Second Edition (BDI-II) (depression), at each of five visits over a period of 6 months. Results Signs of Lyme disease disappeared post-treatment; however, new-onset patient-reported symptoms increased or plateaued over time. At 6 months, 36% of patients reported new-onset fatigue, 20% widespread pain, and 45% neurocognitive difficulties. However, less than 10% reported greater than “minimal” depression across the entire period. Those with PTLDS (36%) did not differ significantly from those without with respect to demographics, pre-treatment SF-36, and BDI-II scores. Statistically significant differences were found over time on the Role Physical, Vitality, Social Functioning, Role Emotional, and Mental Health subscales (with a trend toward significance for the remaining three subscales of Physical Functioning, Bodily Pain, and General Health) of the SF-36 between those with an eventual PTLDS diagnosis and those without when measured at 6 months. Conclusions Unlike clinical signs of Lyme disease, new-onset symptoms are reported by a subset of participants without evidence of depressive symptomatology. Patients who developed PTLDS had significantly lower life functioning compared to those without PTLDS. We propose future avenues for researching infection-triggered symptoms resulting from multiple mechanisms.

1 June 2013 in International Journal of Infectious Diseases
Verified
Journal Article
Closed access
JAJohn N. Aucott
John N. Aucott
LCLauren A. Crowder
Lauren A. Crowder
KKKathleen B. Kortte
Kathleen B. Kortte

1 September 2016 in Clinical and Vaccine Immunology
Verified
Journal Article
Closed access
PDF file
JAJohn N. Aucott
John N. Aucott
MSMark J. Soloski
Mark J. Soloski
ARAlison W. Rebman
Alison W. Rebman
LCLauren A. Crowder
Lauren A. Crowder
LLLauren J. Lahey
Lauren J. Lahey
KBKathleen T. Bechtold
Kathleen T. Bechtold
Approximately 10% to 20% of patients optimally treated for early Lyme disease develop persistent symptoms of unknown pathophysiology termed posttreatment Lyme disease syndrome (PTLDS). The objective of this study was to investigate associations between PTLDS and immune mediator levels during acute illness and at several time points following treatment. Seventy-six participants with physician-documented erythema migrans and 26 healthy controls with no history of Lyme disease were enrolled. Sixty-four cytokines, chemokines, and inflammatory markers were measured at each visit for a total of 6 visits over 1 year. An operationalized definition of PTLDS incorporating symptoms and functional impact was applied at 6 months and 1 year following treatment completion, and clinical outcome groups were defined as the return-to-health, symptoms-only, and PTLDS groups. Significance analysis of microarrays identified 7 of the 64 immune mediators to be differentially regulated by group. Generalized logit regressions controlling for potential confounders identified posttreatment levels of the T-cell chemokine CCL19 to be independently associated with clinical outcome group. Receiver operating characteristic analysis identified a CCL19 cutoff of >111.67 pg/ml at 1 month following treatment completion to be 82% sensitive and 83% specific for later PTLDS. We speculate that persistently elevated CCL19 levels among participants with PTLDS may reflect ongoing, immune-driven reactions at sites distal to secondary lymphoid tissue. Our findings suggest the relevance of CCL19 both during acute infection and as an immunologic risk factor for PTLDS during the posttreatment phase. Identification of a potential biomarker predictor for PTLDS provides the opportunity to better understand its pathophysiology and to develop early interventions in the context of appropriate and specific clinical information.

1 April 2020 in Transfusion Medicine Reviews
Verified
Journal Article
Closed access
RDRoger Y. Dodd
Roger Y. Dodd
LCLauren A. Crowder
Lauren A. Crowder
JHJames M. Haynes
James M. Haynes
ENEdward P. Notari
Edward P. Notari
SSSusan L. Stramer
Susan L. Stramer
WSWhitney R. Steele
Whitney R. Steele

16 April 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMark J. Soloski
Mark J. Soloski
LCLauren A. Crowder
Lauren A. Crowder
LLLauren J. Lahey
Lauren J. Lahey
CWCatriona A. Wagner
Catriona A. Wagner
WRWilliam H. Robinson
William H. Robinson
JAJohn N. Aucott
John N. Aucott
Chemokines and cytokines are key signaling molecules that orchestrate the trafficking of immune cells, direct them to sites of tissue injury and inflammation and modulate their states of activation and effector cell function. We have measured, using a multiplex-based approach, the levels of 58 immune mediators and 7 acute phase markers in sera derived from of a cohort of patients diagnosed with acute Lyme disease and matched controls. This analysis identified a cytokine signature associated with the early stages of infection and allowed us to identify two subsets (mediator-high and mediator-low) of acute Lyme patients with distinct cytokine signatures that also differed significantly (p<0.0005) in symptom presentation. In particular, the T cell chemokines CXCL9 (MIG), CXCL10 (IP-10) and CCL19 (MIP3B) were coordinately increased in the mediator-high group and levels of these chemokines could be associated with seroconversion status and elevated liver function tests (p = 0.027 and p = 0.021 respectively). There was also upregulation of acute phase proteins including CRP and serum amyloid A. Consistent with the role of CXCL9/CXCL10 in attracting immune cells to the site of infection, CXCR3+ CD4 T cells are reduced in the blood of early acute Lyme disease (p = 0.01) and the decrease correlates with chemokine levels (p = 0.0375). The levels of CXCL9/10 did not relate to the size or number of skin lesions but elevated levels of serum CXCL9/CXCL10 were associated with elevated liver enzymes levels. Collectively these results indicate that the levels of serum chemokines and the levels of expression of their respective chemokine receptors on T cell subsets may prove to be informative biomarkers for Lyme disease and related to specific disease manifestations.

13 June 2014 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
ARAlison W. Rebman
Alison W. Rebman
LCLauren A. Crowder
Lauren A. Crowder
AKAllison Kirkpatrick
Allison Kirkpatrick
JAJohn N. Aucott
John N. Aucott